Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease

dc.contributor.authorUysal, Pelin
dc.contributor.authorSimsek, Gonul
dc.contributor.authorDurmus, Sinem
dc.contributor.authorSozer, Volkan
dc.contributor.authorAksan, Hulya
dc.contributor.authorYurt, Sibel
dc.contributor.authorCuhadaroglu, Caglar
dc.contributor.authorKosar, Filiz
dc.contributor.authorGelisgen, Remise
dc.contributor.authorUzun, Hafize
dc.date.accessioned2023-02-21T12:38:07Z
dc.date.available2023-02-21T12:38:07Z
dc.date.issued2019-01-01
dc.description.abstractBackground: Antimicrobial peptides are effectors of host defence against infection and inflammation and can encourage wound repair. Objectives: The objectives of this study were to investigate the plasma antimicrobial peptide LL-37 and nuclear factor-kappaB (NF-kappa B) levels in patients with stable COPD compared with a control group and to highlight their importance in immune inflammation. Methods: One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study. The COPD patients were classified into four groups based on FEV1 (groups I-IV) and also divided into ``low-risk and high-risk{''} groups (groups A-B {[}low risk], C-D {[}high risk]). Results: Plasma LL-37 levels were significantly lower while plasma NF-kappa B levels of the COPD patients were significantly higher than those of the control subjects (P<0.001, both). LL-37 levels were significantly lower in group IV than in groups I, II, and III (P<0.01, all). NF-kappa B levels were significantly higher in groups III and IV than in groups I and II (P<0.05, both). There was a positive correlation between FEV1 and FEV1/FVC in all COPD patients (r=0.742, P<0.001) and in group D (r=0.741, P<0.001). Furthermore, there was an inverse correlation between LL-37 and NF-kappa B in both the groups C (r=-0.566, P<0.001) and D (r=-0.694, P<0.001) and group C+ D combined (r=-0.593, P<0.001). Furthermore, in group C, LL-37 and FEV1 were positively correlated (r=0.633, P<0.001). Conclusion: Our study indicated that plasma LL-37 and NF-kappa B may play an important role in chronic immune inflammation. Decreased LL-37 levels may be particularly high risk for patients in stage IV disease. The role of LL-37 as a target for treatment of the immune system and COPD must be widely evaluated.
dc.description.pages321-330
dc.description.volume14
dc.identifier.doi10.2147/COPD.S185602
dc.identifier.urihttps://hdl.handle.net/11443/2341
dc.identifier.urihttp://dx.doi.org/10.2147/COPD.S185602
dc.identifier.wosWOS:000456659400001
dc.publisherDOVE MEDICAL PRESS LTD
dc.relation.ispartofINTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
dc.subjectCOPD
dc.subjectinflammation
dc.subjectantimicrobial peptide LL-37
dc.subjectnuclear factor kappaB
dc.titleEvaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease
dc.typeArticle

Files

Collections